These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32835535)

  • 21. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor.
    Schilling U; Dingemanse J; Dobrow M; Baumann M; Riederer MA; Juif PE; Ufer M
    Thromb Haemost; 2021 Jun; 121(6):755-766. PubMed ID: 33412611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
    Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
    Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
    Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel-drug interactions.
    Bates ER; Lau WC; Angiolillo DJ
    J Am Coll Cardiol; 2011 Mar; 57(11):1251-63. PubMed ID: 21392639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis.
    Andreou I; Briasoulis A; Pappas C; Ikonomidis I; Alexopoulos D
    Cardiovasc Drugs Ther; 2018 Jun; 32(3):287-294. PubMed ID: 29766335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clopidogrel Hypersensitivity: Overview of the Problem.
    Savage MP; Fischman DL
    Curr Vasc Pharmacol; 2019; 17(2):108-109. PubMed ID: 30124153
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis.
    Serenelli M; Pavasini R; Vitali F; Tonet E; Bilotta F; Parodi G; Campo G
    J Thromb Haemost; 2019 Jun; 17(6):944-950. PubMed ID: 30884109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence-based oral antiplatelet therapy among hospitalized Chinese patients with acute myocardial infarction: results from the Chinese acute myocardial infarction registry.
    Tang X; Liu L; Yang J; Gao Z; Zhao X; Qiao S; Gao R; Wang Z; Yuan J; Yang Y
    BMC Cardiovasc Disord; 2021 Jun; 21(1):299. PubMed ID: 34126921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic Window of Clopidogrel and Ticagrelor in Patients With Critical Limb-Threatening Ischemia.
    Dhillon AS; Caro J; Tun H; Armstrong DG; Rowe V; Shavelle DM; Clavijo LC
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):158-163. PubMed ID: 31550912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project.
    Zhao G; Zhou M; Ma C; Huo Y; Smith SC; Fonarow GC; Ge J; Han Y; Liu J; Hao Y; Liu J; Wang X; Taubert KA; Morgan L; Zhao D; Nie S;
    J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29602767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.
    Ferri N; Corsini A; Bellosta S
    Drugs; 2013 Oct; 73(15):1681-709. PubMed ID: 24114622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study.
    Fanaroff AC; Kaltenbach LA; Peterson ED; Akhter MW; Effron MB; Henry TD; Wang TY
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29437596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial.
    Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM;
    Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clopidogrel Pharmacogenetics.
    Pereira NL; Rihal CS; So DYF; Rosenberg Y; Lennon RJ; Mathew V; Goodman SG; Weinshilboum RM; Wang L; Baudhuin LM; Lerman A; Hasan A; Iturriaga E; Fu YP; Geller N; Bailey K; Farkouh ME
    Circ Cardiovasc Interv; 2019 Apr; 12(4):e007811. PubMed ID: 30998396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y
    Guo CG; Chen L; Chan EW; Cheung KS; Isshiki T; Wong ICK; Leung WK
    Aliment Pharmacol Ther; 2019 Jan; 49(1):7-19. PubMed ID: 30506985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial.
    Reed GW; Cannon CP; Waalen J; Teirstein PS; Tanguay JF; Berger PB; Angiolillo DJ; Price MJ
    Catheter Cardiovasc Interv; 2017 Feb; 89(2):190-198. PubMed ID: 26909669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
    Bernlochner I; Byrne RA; Kastrati A; Sibbing D
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.